<DOC>
	<DOCNO>NCT00197158</DOCNO>
	<brief_summary>GSK Biologicals ' currently license multidose hepatitis B vaccine compare currently license monodose hepatitis B vaccine population well document hepatitis B immunological response vaccine ( Belgium ) .</brief_summary>
	<brief_title>Comparison Monodose Multidose Presentations GSK Biologicals ' Hepatitis B Vaccine Terms Immune Response</brief_title>
	<detailed_description>Randomized study two group . One group receive GSK 's multidose hepatitis B vaccine group receive GSK 's monodose hepatitis B vaccine</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Inclusion criterion : A male female &gt; = 18 year age Written inform consent obtain subject . Free obvious health problem establish medical history clinical examination enter study . If subject female , must nonchildbearing potential , i.e . either surgically sterilize one year postmenopausal ; , childbearing potential , must abstinent use adequate contraceptive precaution 30 day prior vaccination , negative pregnancy test must agree continue precaution two month completion vaccination series . Exclusion criterion : Use investigational nonregistered drug vaccine study vaccine study period . Chronic administration ( defined 14 day ) immunosuppressant immunemodifying drug within six month prior first vaccine dose . ( For corticosteroid , mean prednisone , equivalent , great equal 0.5 mg/kg/day . Inhaled topical steroid allow . ) Planned administration/ administration vaccine foreseen study protocol within 30 day first dose vaccine . Previous vaccination hepatitis B History hepatitis B infection Known exposure hepatitis B within previous 6 week Any confirm suspected immunosuppressive immunodeficient condition , include human immunodeficiency virus ( HIV ) infection . A family history congenital hereditary immunodeficiency . History allergic disease reaction likely exacerbate component vaccine ( ) . Acute disease time enrolment . ( Acute disease define presence moderate severe illness without fever . All vaccine administer person minor illness diarrhoea , mild upper respiratory infection without lowgrade febrile illness , i.e . Oral temperature &lt; 37.5째C ( 99.5째F ) / Axillary temperature &lt; 37.5째C ( 99.5째F ) . Acute chronic , clinically significant pulmonary , cardiovascular , hepatic renal functional abnormality , determine physical examination laboratory screen test . Administration immunoglobulins and/or blood product within three month precede first dose study vaccine plan administration study period . Pregnant lactate female . Female plan become pregnant planning discontinue contraceptive precaution study period .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>